IPSC (Century Therapeutics) FCF Margin % : -580.47% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Century Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-24.22 Mil. Century Therapeutics's Revenue for the three months ended in Dec. 2024 was $4.17 Mil. Therefore, Century Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -580.47%.

As of today, Century Therapeutics's current FCF Yield % is -274.47%.

The historical rank and industry rank for Century Therapeutics's FCF Margin % or its related term are showing as below:

IPSC' s FCF Margin % Range Over the Past 10 Years
Min: -4567.52 Med: -1673.84 Max: -318.37
Current: -1683.44

During the past 6 years, the highest FCF Margin % of Century Therapeutics was -318.37%. The lowest was -4567.52%. And the median was -1673.84%.

IPSC's FCF Margin % is ranked worse than
81.62% of 1012 companies
in the Biotechnology industry
Industry Median: -131.635 vs IPSC: -1683.44

Century Therapeutics FCF Margin % Historical Data

The historical data trend for Century Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics FCF Margin % Chart

Century Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-318.37

-4,567.52

-1,673.84

Century Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-10,152.99	-3,600.82	-3,579.38	-3,581.80	-580.47

Competitive Comparison of Century Therapeutics's FCF Margin %

For the Biotechnology subindustry, Century Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Century Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Century Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Century Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-110.289	/	6.589
	=	-1,673.84 %

Century Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-24.223	/	4.173
	=	-580.47 %

Century Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Century Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104

Website

https://www.centurytx.com

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Executives

Adrienne Farid	officer: Chief Operations Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti	officer: Chief Technology Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr	officer: VP of Finance and Operations	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Daphne Quimi	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Luis Borges	officer: Chief Scientific Officer	TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez	director	ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky	officer: President of R&D	C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Osvaldo Flores	officer: Chief Executive Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104